Risk Factors of Extended-Spectrum Beta-Lactamases-Producing Escherichia coli Community Acquired Urinary Tract Infections: A Systematic Review

References

• Lee DS, Lee S-J, Choe H-S. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed Res Int. 2018;2018:7656752. doi:10.1155/2018/765675230356438
   PubMed Web of Science ®Google Scholar
• Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: types, epidemiology and treatment. Saudi J Biol Sci. 2015;22(1):90–101. doi:10.1016/j.sjbs.2014.08.00225561890
   PubMed Web of Science ®Google Scholar
• Chervet D, Lortholary O, Zahar J-R, Dufougeray A, Pilmis B, Partouche H. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015. Med Mal Infect. 2018;48(3):188–192. doi:10.1016/j.medmal.2017.09.01329054298
   PubMed Web of Science ®Google Scholar
• Arana DM, Rubio M, Alós J-I. Evolution of antibiotic multiresistance in Escherichia coli and Klebsiella pneumoniae isolates from urinary tract infections: a 12-year analysis (2003–2014). Enferm Infecc Microbiol Clin. 2017;35(5):293–298. doi:10.1016/j.eimc.2016.02.01827056582
   PubMed Web of Science ®Google Scholar
• Picozzi S, Ricci C, Gaeta M, et al. Do we really know the prevalence of multi-drug resistant Escherichia coli in the territorial and nosocomial population? Urol Ann. 2013;5(1):25–29. doi:10.4103/0974-7796.10696223662006
   PubMedGoogle Scholar
• Patwardhan V, Kumar D, Goel V, Singh S. Changing prevalence and antibiotic drug resistance pattern of pathogens seen in community-acquired pediatric urinary tract infections at a tertiary care hospital of North India. J Lab Physicians. 2017;9(4):264–268. doi:10.4103/JLP.JLP_149_1628966488
   PubMedGoogle Scholar
• Balasubramanian S, Kuppuswamy D, Padmanabhan S, Chandramohan V, Amperayani S. Extended-spectrum beta-lactamase-producing community-acquired urinary tract infections in children: chart review of risk factors. J Glob Infect Dis. 2018;10(4):222–225. doi:10.4103/0974-777X.24639130581265
   PubMed Web of Science ®Google Scholar
• Fatima S, Muhammad IN, Usman S, Jamil S, Khan MN, Khan SI. Incidence of multidrug resistance and extended-spectrum beta-lactamase expression in community-acquired urinary tract infection among different age groups of patients. Indian J Pharmacol. 2018;50(2):69–74. doi:10.4103/ijp.IJP_200_1730100654
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Essential medicines and health products. 2 27, 2017 Available from:https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed 106, 2020.
   Google Scholar
• Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128–142. doi:10.3904/kjim.2012.27.2.12822707882
   PubMed Web of Science ®Google Scholar
• Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The growing genetic and functional diversity of extended spectrum beta-lactamases. Biomed Res Int. 2018;2018:9519718. doi:10.1155/2018/951971829780833
   PubMed Web of Science ®Google Scholar
• Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents. 2012;39(1):45–51. doi:10.1016/j.ijantimicag.2011.09.01322055529
   PubMed Web of Science ®Google Scholar
• Tandogdu Z, Wagenlehner FME. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73–79. doi:10.1097/QCO.000000000000022826694621
   PubMed Web of Science ®Google Scholar
• Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13. doi:10.1016/j.idc.2013.09.00324484571
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance: global report on surveillance [Internet]. 2014 Available from: https://apps.who.int/iris/handle/10665/112642. Accessed 418, 2019.
   Google Scholar
• Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations [Internet]. 2016 Available from: https://amr-review.org/. Accessed 418, 2019.
   Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics [Internet]. 2017 Available from: http://apps.who.int/medicinedocs/en/m/abstract/Js23171en/. Accessed 418, 2019.
   Google Scholar
• Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung KH. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J. 2018;26(5):678–684. doi:10.1016/j.jsps.2018.02.02329991911
   PubMed Web of Science ®Google Scholar
• Costel EE, Mitchell S, Kaiser AB. Abbreviated surveillance of nosocomial urinary tract infections: a new approach. Infect Control. 1985;6(1):11–13. doi:10.1017/S01959417000624333843988
   PubMedGoogle Scholar
• Schoonjans F. MedCalc statistical software [Internet]. MedCalc Available from: https://www.medcalc.org/. Accessed 418, 2019.
   Google Scholar
• Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991.
   Google Scholar
• Wells G, Shea B, O’Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyzes. Ottawa Hospital Research Institute. 2009.
   Google Scholar
• Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health. 2013;13:154. doi:10.1186/1471-2458-13-15423421987
   PubMed Web of Science ®Google Scholar
• Blanco VM, Maya JJ, Correa A, et al. [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia]. Enferm Infecc Microbiol Clin. 2016;34(9):559–565. doi:10.1016/j.eimc.2015.11.01726774256
   PubMed Web of Science ®Google Scholar
• Nisha KV, Veena SA, Rathika SD, Vijaya SM, Avinash SK. Antimicrobial susceptibility, risk factors and prevalence of bla cefotaximase, temoneira, and sulfhydryl variable genes among Escherichia coli in community-acquired pediatric urinary tract infection. J Lab Physicians. 2017;9(3):156–162. doi:10.4103/0974-2727.20826228706384
   PubMedGoogle Scholar
• Pérez Heras I, Sanchez-Gomez JC, Beneyto-Martin P, Ruano-de-Pablo L, Losada-Pinedo B. Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: prevalence, risk factors, and resistances. Medicine. 2017;96(50):e8571. doi:10.1097/MD.000000000000857129390257
   PubMed Web of Science ®Google Scholar
• Hertz FB, Schønning K, Rasmussen SC, et al. Epidemiological factors associated with ESBL- and non ESBL-producing E. coli causing urinary tract infection in general practice. Infect Dis (Lond). 2016;48(3):241–245. doi:10.3109/23744235.2015.110389526523346
   PubMed Web of Science ®Google Scholar
• Kang C-I, Wi YM, Lee MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012;50(2):312–317. doi:10.1128/JCM.06002-1122162561
   PubMed Web of Science ®Google Scholar
• Savatmorigkorngul S, Poowarattanawiwit P, Sawanyawisuth K, Sittichanbuncha Y. Factors associated with extended spectrum β-lactamase producing escherichia coli in community-acquired urinary tract infection at hospital emergency department, Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 2016;47(2):227–233.27244961
   PubMed Web of Science ®Google Scholar
• Park SH, Choi S-M, Lee D-G, et al. Impact of extended-spectrum β-lactamase production on treatment outcomes of acute pyelonephritis caused by Escherichia coli in patients without health care-associated risk factors. Antimicrob Agents Chemother. 2015;59(4):1962–1968. doi:10.1128/AAC.04821-1425583722
   PubMed Web of Science ®Google Scholar
• Artero A, Esparcia A, Alberola J, Madrazo M, Nogueira JM, Eiros JM. Prospective cohort study of risk factors for extended-spectrum ß-lactamase-producing Escherichia coli urinary tract infections in elderly patients admitted to hospital. Int J Clin Pract. 2017;71:9. doi:10.1111/ijcp.13001
   Web of Science ®Google Scholar
• Fan N-C, Chen -H-H, Chen C-L, et al. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014;47(5):399–405. doi:10.1016/j.jmii.2013.05.00623834784
   PubMedGoogle Scholar
• Ozdogan FN, Demirdal T, Nemli SA. Risk factors for community acquired urinary tract infections caused by extended spectrum beta-lactamase (ESBL) producing Escherichia coli. In: European Congress of Clinical Microbiology & Infectious Diseases 2015 [Internet]; 2015; Copenhague, Danemark: ESCMID; Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/. Accessed 42, 2019.
   Google Scholar
• Toumi A, Hafsa M, Kadri Y. Risk factors for community-acquired acute pyelonephritis caused by extended-spectrum beta-lactamase-producing Escherichia coli in a university hospital in Tunisia. In: European Congress of Clinical Microbiology & Infectious Diseases 2015 [Internet]; 2015; Copenhague, Danemark: ESCMID; Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/?q=toumi&id=2173&L=0&x=26&y=26. Accessed 42, 2019.
   Google Scholar
• Søraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae – a case-control study in a low prevalence country. PLoS One. 2013;8(7):e69581. doi:10.1371/journal.pone.006958123936052
   PubMed Web of Science ®Google Scholar
• Calbo E, Romaní V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J Antimicrob Chemother. 2006;57(4):780–783. doi:10.1093/jac/dkl03516492721
   PubMed Web of Science ®Google Scholar
• Azap OK, Arslan H, Serefhanoğlu K, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16(2):147–151. doi:10.1111/j.1469-0691.2009.02941.x19689464
   PubMed Web of Science ®Google Scholar
• Søgaard M, Heide-Jørgensen U, Vandenbroucke JP, Schønheyder HC, Vandenbroucke-Grauls CMJE. Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study. Clin Microbiol Infect. 2017;23(12):952–960. doi:10.1016/j.cmi.2017.03.02628377310
   PubMed Web of Science ®Google Scholar
• Castillo-Tokumori F, Irey-Salgado C, Málaga G. Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study. Int J Infect Dis. 2017;55:16–19. doi:10.1016/j.ijid.2016.12.00727979787
   PubMed Web of Science ®Google Scholar
• Tham J, Odenholt I, Walder M, Andersson L, Melander E. Risk factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli in a county of southern Sweden. Infect Drug Resist. 2013;6:93–97. doi:10.2147/IDR.S4629024082789
   PubMedGoogle Scholar
• Arcilla MS, van Hattem JM, Haverkate MR, et al. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis. 2017;17(1):78–85. doi:10.1016/S1473-3099(16)30319-X27751772
   PubMed Web of Science ®Google Scholar
• Friedman ND, Kaye KS, Stout JE, et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791–797. doi:10.7326/0003-4819-137-10-200211190-0000712435215
   PubMed Web of Science ®Google Scholar
• Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–166. doi:10.1016/S1473-3099(08)70041-018291338
   PubMed Web of Science ®Google Scholar
• Al-Otaibi FE, Bukhari EE. Clinical and laboratory profiles of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care center in central Saudi Arabia. Saudi Med J. 2013;34(2):171–176.23396464
   PubMed Web of Science ®Google Scholar
• Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66(9):891–896. doi:10.1111/j.1742-1241.2012.02991.x22897466
   PubMed Web of Science ®Google Scholar
• Köck R, Daniels-Haardt I, Becker K, et al. Carbapenem-resistant Enterobacteriaceae in wildlife, food-producing, and companion animals: a systematic review. Clin Microbiol Infect. 2018;24(12):1241–1250. doi:10.1016/j.cmi.2018.04.00429654871
   PubMed Web of Science ®Google Scholar
• Lazarus B, Paterson DL, Mollinger JL, Rogers BA. Do human extraintestinal Escherichia coli infections resistant to expanded-spectrum cephalosporins originate from food-producing animals? A systematic review. Clin Infect Dis. 2015;60(3):439–452. doi:10.1093/cid/ciu78525301206
   PubMed Web of Science ®Google Scholar
• Jørgensen SB, Søraas AV, Arnesen LS, Leegaard TM, Sundsfjord A, Jenum PA. A comparison of extended spectrum β-lactamase producing Escherichia coli from clinical, recreational water and wastewater samples associated in time and location. PLoS One. 2017;12(10):e0186576. doi:10.1371/journal.pone.018657629040337
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55(7):3485–3490. doi:10.1128/AAC.00009-1121537020
   PubMed Web of Science ®Google Scholar
• Johnson SW, Anderson DJ, May DB, Drew RH. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol. 2013;34(4):385–392. doi:10.1086/66985823466912
   PubMed Web of Science ®Google Scholar